{"id":18060,"date":"2020-12-11T20:24:23","date_gmt":"2020-12-11T20:24:23","guid":{"rendered":"https:\/\/sbpt.org.br\/portal\/?p=18060"},"modified":"2020-12-11T20:24:23","modified_gmt":"2020-12-11T20:24:23","slug":"ivacaftor-fibrose-cistica-2020","status":"publish","type":"post","link":"https:\/\/sbpt.org.br\/portal\/ivacaftor-fibrose-cistica-2020\/","title":{"rendered":"Conitec emite parecer favor\u00e1vel \u00e0 incorpora\u00e7\u00e3o do ivacaftor para a fibrose c\u00edstica"},"content":{"rendered":"<p style=\"text-align: justify\">A Comiss\u00e3o Nacional de Incorpora\u00e7\u00e3o de Tecnologias no Sistema \u00danico de Sa\u00fade (SUS), Conitec, emitiu um parecer favor\u00e1vel \u00e0 incorpora\u00e7\u00e3o do uso de ivacaftor em pacientes com muta\u00e7\u00f5es classe III em fibrose c\u00edstica.<\/p>\n<p style=\"text-align: justify\">Ap\u00f3s analisar as contribui\u00e7\u00f5es recebidas nas consultas p\u00fablicas e reuni\u00f5es de esclarecimento, o Minist\u00e9rio da Sa\u00fade foi a favor do uso de ivacaftor para pacientes acima de seis anos que apresentem uma das seguintes muta\u00e7\u00f5es de gating no gene CFTR (classe III): G55ID, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N ou S549R.<\/p>\n<p style=\"text-align: justify\">A Secretaria Executiva da Conitec analisou os estudos do medicamento quanto \u00e0 seguran\u00e7a, efic\u00e1cia e economia, comparando com o tratamento de suporte e seus sintomas e considerando tanto os benef\u00edcios na capacidade respirat\u00f3ria, qualidade de vida e ganho de peso como tamb\u00e9m os efeitos adversos.<\/p>\n<p style=\"text-align: justify\">A Comiss\u00e3o Cient\u00edfica de Fibrose C\u00edstica da SBPT, que acompanhou as reuni\u00f5es e contribuiu com as recomenda\u00e7\u00f5es, celebrou a decis\u00e3o pela incorpora\u00e7\u00e3o.<\/p>\n<!-- AddThis Advanced Settings generic via filter on the_content --><!-- AddThis Share Buttons generic via filter on the_content -->","protected":false},"excerpt":{"rendered":"<p>A Comiss\u00e3o Nacional de Incorpora\u00e7\u00e3o de Tecnologias no Sistema \u00danico de Sa\u00fade (SUS), Conitec, emitiu um parecer favor\u00e1vel \u00e0 incorpora\u00e7\u00e3o do uso de ivacaftor em pacientes com muta\u00e7\u00f5es classe III em fibrose c\u00edstica. Ap\u00f3s analisar as contribui\u00e7\u00f5es recebidas nas consultas p\u00fablicas e reuni\u00f5es de esclarecimento, o Minist\u00e9rio da Sa\u00fade foi a favor do uso de [&hellip;]<!-- AddThis Advanced Settings generic via filter on get_the_excerpt --><!-- AddThis Share Buttons generic via filter on get_the_excerpt --><\/p>\n","protected":false},"author":3,"featured_media":17988,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"ngg_post_thumbnail":0,"footnotes":""},"categories":[68],"tags":[164,903],"class_list":["post-18060","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-noticias","tag-fibrose-cistica","tag-ivacaftor"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Conitec emite parecer favor\u00e1vel \u00e0 incorpora\u00e7\u00e3o do ivacaftor para a fibrose c\u00edstica<\/title>\n<meta name=\"description\" content=\"A Comiss\u00e3o Nacional de Incorpora\u00e7\u00e3o de Tecnologias no Sistema \u00danico de Sa\u00fade (SUS), Conitec, emitiu um parecer favor\u00e1vel \u00e0 incorpora\u00e7\u00e3o do uso de ivacaftor em pacientes com muta\u00e7\u00f5es classe III em fibrose c\u00edstica.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/sbpt.org.br\/portal\/ivacaftor-fibrose-cistica-2020\/\" \/>\n<meta property=\"og:locale\" content=\"pt_BR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Conitec emite parecer favor\u00e1vel \u00e0 incorpora\u00e7\u00e3o do ivacaftor para a fibrose c\u00edstica\" \/>\n<meta property=\"og:description\" content=\"A Comiss\u00e3o Nacional de Incorpora\u00e7\u00e3o de Tecnologias no Sistema \u00danico de Sa\u00fade (SUS), Conitec, emitiu um parecer favor\u00e1vel \u00e0 incorpora\u00e7\u00e3o do uso de ivacaftor em pacientes com muta\u00e7\u00f5es classe III em fibrose c\u00edstica.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/sbpt.org.br\/portal\/ivacaftor-fibrose-cistica-2020\/\" \/>\n<meta property=\"og:site_name\" content=\"sbpt.org.br\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/pneumosbpt\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-11T20:24:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/sbpt.org.br\/portal\/wp-content\/uploads\/2020\/12\/conitec_novo_destaque.png\" \/>\n\t<meta property=\"og:image:width\" content=\"350\" \/>\n\t<meta property=\"og:image:height\" content=\"255\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Comunica\u00e7\u00e3o SBPT\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@pneumosbpt\" \/>\n<meta name=\"twitter:site\" content=\"@pneumosbpt\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Comunica\u00e7\u00e3o SBPT\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. tempo de leitura\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minuto\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/sbpt.org.br\\\/portal\\\/ivacaftor-fibrose-cistica-2020\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/sbpt.org.br\\\/portal\\\/ivacaftor-fibrose-cistica-2020\\\/\"},\"author\":{\"name\":\"Comunica\u00e7\u00e3o SBPT\",\"@id\":\"https:\\\/\\\/sbpt.org.br\\\/portal\\\/#\\\/schema\\\/person\\\/adba7f33cf32721354590c6f0eb852d4\"},\"headline\":\"Conitec emite parecer favor\u00e1vel \u00e0 incorpora\u00e7\u00e3o do ivacaftor para a fibrose c\u00edstica\",\"datePublished\":\"2020-12-11T20:24:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/sbpt.org.br\\\/portal\\\/ivacaftor-fibrose-cistica-2020\\\/\"},\"wordCount\":199,\"publisher\":{\"@id\":\"https:\\\/\\\/sbpt.org.br\\\/portal\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/sbpt.org.br\\\/portal\\\/ivacaftor-fibrose-cistica-2020\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/sbpt.org.br\\\/portal\\\/wp-content\\\/uploads\\\/2020\\\/12\\\/conitec_novo_destaque.png\",\"keywords\":[\"fibrose cistica\",\"ivacaftor\"],\"articleSection\":[\"Not\u00edcias\"],\"inLanguage\":\"pt-BR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/sbpt.org.br\\\/portal\\\/ivacaftor-fibrose-cistica-2020\\\/\",\"url\":\"https:\\\/\\\/sbpt.org.br\\\/portal\\\/ivacaftor-fibrose-cistica-2020\\\/\",\"name\":\"Conitec emite parecer favor\u00e1vel \u00e0 incorpora\u00e7\u00e3o do ivacaftor para a fibrose c\u00edstica\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/sbpt.org.br\\\/portal\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/sbpt.org.br\\\/portal\\\/ivacaftor-fibrose-cistica-2020\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/sbpt.org.br\\\/portal\\\/ivacaftor-fibrose-cistica-2020\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/sbpt.org.br\\\/portal\\\/wp-content\\\/uploads\\\/2020\\\/12\\\/conitec_novo_destaque.png\",\"datePublished\":\"2020-12-11T20:24:23+00:00\",\"description\":\"A Comiss\u00e3o Nacional de Incorpora\u00e7\u00e3o de Tecnologias no Sistema \u00danico de Sa\u00fade (SUS), Conitec, emitiu um parecer favor\u00e1vel \u00e0 incorpora\u00e7\u00e3o do uso de ivacaftor em pacientes com muta\u00e7\u00f5es classe III em fibrose c\u00edstica.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/sbpt.org.br\\\/portal\\\/ivacaftor-fibrose-cistica-2020\\\/#breadcrumb\"},\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/sbpt.org.br\\\/portal\\\/ivacaftor-fibrose-cistica-2020\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/sbpt.org.br\\\/portal\\\/ivacaftor-fibrose-cistica-2020\\\/#primaryimage\",\"url\":\"https:\\\/\\\/sbpt.org.br\\\/portal\\\/wp-content\\\/uploads\\\/2020\\\/12\\\/conitec_novo_destaque.png\",\"contentUrl\":\"https:\\\/\\\/sbpt.org.br\\\/portal\\\/wp-content\\\/uploads\\\/2020\\\/12\\\/conitec_novo_destaque.png\",\"width\":350,\"height\":255},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/sbpt.org.br\\\/portal\\\/ivacaftor-fibrose-cistica-2020\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/sbpt.org.br\\\/portal\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Conitec emite parecer favor\u00e1vel \u00e0 incorpora\u00e7\u00e3o do ivacaftor para a fibrose c\u00edstica\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/sbpt.org.br\\\/portal\\\/#website\",\"url\":\"https:\\\/\\\/sbpt.org.br\\\/portal\\\/\",\"name\":\"sbpt.org.br\",\"description\":\"Sociedade Brasileira de Pneumologia e Tisiologia\",\"publisher\":{\"@id\":\"https:\\\/\\\/sbpt.org.br\\\/portal\\\/#organization\"},\"alternateName\":\"SBPT\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/sbpt.org.br\\\/portal\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-BR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/sbpt.org.br\\\/portal\\\/#organization\",\"name\":\"sbpt.org.br\",\"url\":\"https:\\\/\\\/sbpt.org.br\\\/portal\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/sbpt.org.br\\\/portal\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/sbpt.org.br\\\/portal\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/logo-sbpt.png\",\"contentUrl\":\"https:\\\/\\\/sbpt.org.br\\\/portal\\\/wp-content\\\/uploads\\\/2026\\\/10\\\/logo-sbpt.png\",\"width\":512,\"height\":512,\"caption\":\"sbpt.org.br\"},\"image\":{\"@id\":\"https:\\\/\\\/sbpt.org.br\\\/portal\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/pneumosbpt\",\"https:\\\/\\\/x.com\\\/pneumosbpt\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/pneumosbpt\\\/\",\"https:\\\/\\\/www.instagram.com\\\/pneumosbpt\\\/\",\"https:\\\/\\\/www.youtube.com\\\/user\\\/socbraspneumol\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/sbpt.org.br\\\/portal\\\/#\\\/schema\\\/person\\\/adba7f33cf32721354590c6f0eb852d4\",\"name\":\"Comunica\u00e7\u00e3o SBPT\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"pt-BR\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/83068fab2f784f5c487104783a7006fb40e8fd85adc44189ac928b9e39fddad8?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/83068fab2f784f5c487104783a7006fb40e8fd85adc44189ac928b9e39fddad8?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/83068fab2f784f5c487104783a7006fb40e8fd85adc44189ac928b9e39fddad8?s=96&d=mm&r=g\",\"caption\":\"Comunica\u00e7\u00e3o SBPT\"},\"url\":\"https:\\\/\\\/sbpt.org.br\\\/portal\\\/author\\\/anahelena\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Conitec emite parecer favor\u00e1vel \u00e0 incorpora\u00e7\u00e3o do ivacaftor para a fibrose c\u00edstica","description":"A Comiss\u00e3o Nacional de Incorpora\u00e7\u00e3o de Tecnologias no Sistema \u00danico de Sa\u00fade (SUS), Conitec, emitiu um parecer favor\u00e1vel \u00e0 incorpora\u00e7\u00e3o do uso de ivacaftor em pacientes com muta\u00e7\u00f5es classe III em fibrose c\u00edstica.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/sbpt.org.br\/portal\/ivacaftor-fibrose-cistica-2020\/","og_locale":"pt_BR","og_type":"article","og_title":"Conitec emite parecer favor\u00e1vel \u00e0 incorpora\u00e7\u00e3o do ivacaftor para a fibrose c\u00edstica","og_description":"A Comiss\u00e3o Nacional de Incorpora\u00e7\u00e3o de Tecnologias no Sistema \u00danico de Sa\u00fade (SUS), Conitec, emitiu um parecer favor\u00e1vel \u00e0 incorpora\u00e7\u00e3o do uso de ivacaftor em pacientes com muta\u00e7\u00f5es classe III em fibrose c\u00edstica.","og_url":"https:\/\/sbpt.org.br\/portal\/ivacaftor-fibrose-cistica-2020\/","og_site_name":"sbpt.org.br","article_publisher":"https:\/\/www.facebook.com\/pneumosbpt","article_published_time":"2020-12-11T20:24:23+00:00","og_image":[{"width":350,"height":255,"url":"https:\/\/sbpt.org.br\/portal\/wp-content\/uploads\/2020\/12\/conitec_novo_destaque.png","type":"image\/png"}],"author":"Comunica\u00e7\u00e3o SBPT","twitter_card":"summary_large_image","twitter_creator":"@pneumosbpt","twitter_site":"@pneumosbpt","twitter_misc":{"Escrito por":"Comunica\u00e7\u00e3o SBPT","Est. tempo de leitura":"1 minuto"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/sbpt.org.br\/portal\/ivacaftor-fibrose-cistica-2020\/#article","isPartOf":{"@id":"https:\/\/sbpt.org.br\/portal\/ivacaftor-fibrose-cistica-2020\/"},"author":{"name":"Comunica\u00e7\u00e3o SBPT","@id":"https:\/\/sbpt.org.br\/portal\/#\/schema\/person\/adba7f33cf32721354590c6f0eb852d4"},"headline":"Conitec emite parecer favor\u00e1vel \u00e0 incorpora\u00e7\u00e3o do ivacaftor para a fibrose c\u00edstica","datePublished":"2020-12-11T20:24:23+00:00","mainEntityOfPage":{"@id":"https:\/\/sbpt.org.br\/portal\/ivacaftor-fibrose-cistica-2020\/"},"wordCount":199,"publisher":{"@id":"https:\/\/sbpt.org.br\/portal\/#organization"},"image":{"@id":"https:\/\/sbpt.org.br\/portal\/ivacaftor-fibrose-cistica-2020\/#primaryimage"},"thumbnailUrl":"https:\/\/sbpt.org.br\/portal\/wp-content\/uploads\/2020\/12\/conitec_novo_destaque.png","keywords":["fibrose cistica","ivacaftor"],"articleSection":["Not\u00edcias"],"inLanguage":"pt-BR"},{"@type":"WebPage","@id":"https:\/\/sbpt.org.br\/portal\/ivacaftor-fibrose-cistica-2020\/","url":"https:\/\/sbpt.org.br\/portal\/ivacaftor-fibrose-cistica-2020\/","name":"Conitec emite parecer favor\u00e1vel \u00e0 incorpora\u00e7\u00e3o do ivacaftor para a fibrose c\u00edstica","isPartOf":{"@id":"https:\/\/sbpt.org.br\/portal\/#website"},"primaryImageOfPage":{"@id":"https:\/\/sbpt.org.br\/portal\/ivacaftor-fibrose-cistica-2020\/#primaryimage"},"image":{"@id":"https:\/\/sbpt.org.br\/portal\/ivacaftor-fibrose-cistica-2020\/#primaryimage"},"thumbnailUrl":"https:\/\/sbpt.org.br\/portal\/wp-content\/uploads\/2020\/12\/conitec_novo_destaque.png","datePublished":"2020-12-11T20:24:23+00:00","description":"A Comiss\u00e3o Nacional de Incorpora\u00e7\u00e3o de Tecnologias no Sistema \u00danico de Sa\u00fade (SUS), Conitec, emitiu um parecer favor\u00e1vel \u00e0 incorpora\u00e7\u00e3o do uso de ivacaftor em pacientes com muta\u00e7\u00f5es classe III em fibrose c\u00edstica.","breadcrumb":{"@id":"https:\/\/sbpt.org.br\/portal\/ivacaftor-fibrose-cistica-2020\/#breadcrumb"},"inLanguage":"pt-BR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/sbpt.org.br\/portal\/ivacaftor-fibrose-cistica-2020\/"]}]},{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/sbpt.org.br\/portal\/ivacaftor-fibrose-cistica-2020\/#primaryimage","url":"https:\/\/sbpt.org.br\/portal\/wp-content\/uploads\/2020\/12\/conitec_novo_destaque.png","contentUrl":"https:\/\/sbpt.org.br\/portal\/wp-content\/uploads\/2020\/12\/conitec_novo_destaque.png","width":350,"height":255},{"@type":"BreadcrumbList","@id":"https:\/\/sbpt.org.br\/portal\/ivacaftor-fibrose-cistica-2020\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/sbpt.org.br\/portal\/"},{"@type":"ListItem","position":2,"name":"Conitec emite parecer favor\u00e1vel \u00e0 incorpora\u00e7\u00e3o do ivacaftor para a fibrose c\u00edstica"}]},{"@type":"WebSite","@id":"https:\/\/sbpt.org.br\/portal\/#website","url":"https:\/\/sbpt.org.br\/portal\/","name":"sbpt.org.br","description":"Sociedade Brasileira de Pneumologia e Tisiologia","publisher":{"@id":"https:\/\/sbpt.org.br\/portal\/#organization"},"alternateName":"SBPT","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/sbpt.org.br\/portal\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-BR"},{"@type":"Organization","@id":"https:\/\/sbpt.org.br\/portal\/#organization","name":"sbpt.org.br","url":"https:\/\/sbpt.org.br\/portal\/","logo":{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/sbpt.org.br\/portal\/#\/schema\/logo\/image\/","url":"https:\/\/sbpt.org.br\/portal\/wp-content\/uploads\/2026\/10\/logo-sbpt.png","contentUrl":"https:\/\/sbpt.org.br\/portal\/wp-content\/uploads\/2026\/10\/logo-sbpt.png","width":512,"height":512,"caption":"sbpt.org.br"},"image":{"@id":"https:\/\/sbpt.org.br\/portal\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/pneumosbpt","https:\/\/x.com\/pneumosbpt","https:\/\/www.linkedin.com\/company\/pneumosbpt\/","https:\/\/www.instagram.com\/pneumosbpt\/","https:\/\/www.youtube.com\/user\/socbraspneumol"]},{"@type":"Person","@id":"https:\/\/sbpt.org.br\/portal\/#\/schema\/person\/adba7f33cf32721354590c6f0eb852d4","name":"Comunica\u00e7\u00e3o SBPT","image":{"@type":"ImageObject","inLanguage":"pt-BR","@id":"https:\/\/secure.gravatar.com\/avatar\/83068fab2f784f5c487104783a7006fb40e8fd85adc44189ac928b9e39fddad8?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/83068fab2f784f5c487104783a7006fb40e8fd85adc44189ac928b9e39fddad8?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/83068fab2f784f5c487104783a7006fb40e8fd85adc44189ac928b9e39fddad8?s=96&d=mm&r=g","caption":"Comunica\u00e7\u00e3o SBPT"},"url":"https:\/\/sbpt.org.br\/portal\/author\/anahelena\/"}]}},"_links":{"self":[{"href":"https:\/\/sbpt.org.br\/portal\/wp-json\/wp\/v2\/posts\/18060","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/sbpt.org.br\/portal\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/sbpt.org.br\/portal\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/sbpt.org.br\/portal\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/sbpt.org.br\/portal\/wp-json\/wp\/v2\/comments?post=18060"}],"version-history":[{"count":0,"href":"https:\/\/sbpt.org.br\/portal\/wp-json\/wp\/v2\/posts\/18060\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/sbpt.org.br\/portal\/wp-json\/wp\/v2\/media\/17988"}],"wp:attachment":[{"href":"https:\/\/sbpt.org.br\/portal\/wp-json\/wp\/v2\/media?parent=18060"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/sbpt.org.br\/portal\/wp-json\/wp\/v2\/categories?post=18060"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/sbpt.org.br\/portal\/wp-json\/wp\/v2\/tags?post=18060"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}